Scholarlink

<p>For many neurodevelopmental disorders, genetic treatment discovery is complicated by non-homology between human and non-human model system genomes. Antisense oligonucleotides (ASOs) influence protein expression by sequence-specific binding of RNA, resulting in targeted degradation or alternative splicing, and thereby provide a promising avenue for clinical therapeutics. Angelman Syndrome (AS), caused by loss-of-function of maternal <i>UBE3A</i>, has emerged as a monogenic neurodevelopmental disorder for which ASO therapy might be particularly amenable due to genomic imprinting. In an AS mouse model, <i>Ube3a</i> reactivation of the paternal allele using ASOs has been previously shown to rescue disease-relevant phenotypes. However, the poor sequence homology between murine and human <i>UBE3A-ATS</i> requires a human model system for screening of ASOs with clinical therapeutic potential. Here we evaluate an ASO targeting <i>UBE3A-ATS</i> using human induced pluripotent stem cell (hiPSC)-derived AS neurons in vitro and in vivo<i>.</i> We assessed the effect of ASO-treatment on cultured AS patient hiPSC-derived neurons through protein and RNA expression analysis. To increase clinical translatability, we designed a platform to evaluate this ASO in vivo by xenotransplantation of hiPSC-derived AS neurons into the brains of neonatal mice, with intracerebroventricular administration of the <i>UBE3A-ATS</i> ASO three weeks later. One week after ASO treatment, we observed in vivo reinstatement of <i>UBE3A</i> expression in xenotransplanted human neurons. These results highlight the potential for a versatile platform to evaluate efficacy of human-specific ASOs, for which AS provides an instructive proof-of-concept for therapeutic reactivation of UBE3A.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A xenotransplantation model for reactivation of paternal UBE3A using human-specific antisense oligonucleotides

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月28日

查看全文
  • Hilde Smeenk,
  • Bas Lendemeijer,
  • Mirle G. Buurma,
  • Michell A. Forgione,
  • Denise E. Slump,
  • Roos A. Monshouwer,
  • Ilse Wallaard,
  • Edwin J. Mientjes,
  • Witte J. G. Hoogendijk,
  • Ype Elgersma,
  • Femke M. S. de Vrij,
  • Steven A. Kushner

摘要

For many neurodevelopmental disorders, genetic treatment discovery is complicated by non-homology between human and non-human model system genomes. Antisense oligonucleotides (ASOs) influence protein expression by sequence-specific binding of RNA, resulting in targeted degradation or alternative splicing, and thereby provide a promising avenue for clinical therapeutics. Angelman Syndrome (AS), caused by loss-of-function of maternal UBE3A, has emerged as a monogenic neurodevelopmental disorder for which ASO therapy might be particularly amenable due to genomic imprinting. In an AS mouse model, Ube3a reactivation of the paternal allele using ASOs has been previously shown to rescue disease-relevant phenotypes. However, the poor sequence homology between murine and human UBE3A-ATS requires a human model system for screening of ASOs with clinical therapeutic potential. Here we evaluate an ASO targeting UBE3A-ATS using human induced pluripotent stem cell (hiPSC)-derived AS neurons in vitro and in vivo. We assessed the effect of ASO-treatment on cultured AS patient hiPSC-derived neurons through protein and RNA expression analysis. To increase clinical translatability, we designed a platform to evaluate this ASO in vivo by xenotransplantation of hiPSC-derived AS neurons into the brains of neonatal mice, with intracerebroventricular administration of the UBE3A-ATS ASO three weeks later. One week after ASO treatment, we observed in vivo reinstatement of UBE3A expression in xenotransplanted human neurons. These results highlight the potential for a versatile platform to evaluate efficacy of human-specific ASOs, for which AS provides an instructive proof-of-concept for therapeutic reactivation of UBE3A.